RESUMO
Objective To explore the relationship between intestinal fatty acid binding protein(FABP2) gene G54A polymorphism and obesity,the effect of mutant 54A FABP2 gene on serum lipids metabolism.Methods The total of 84 subjects with obesity and 60 subjects with normal weight were involved in this study.The G54A FABP2 gene allele and genotype frequencies were detected by polymerase chain reaction (PCR)-restriction fragment length polymorphism(RFLP) technology.The automatic biochemical Analyzer was used to detect triglyceride(TG),high-density lipoprotein cholesterol(HDL-C) and low-density lipoprotein cholesterol(LDL-C) levels.Results The results of study on FABP2 gene polymorphism revealed as followed:in obese groups,the frequencies of GG,GA,A/A genotypes was 19.0%(16/84),73.8%(62/84) and 7.2%(6/84),respectively;in control group,the frequencies of G/G,G/A,A/A genotypes was 38.3%(23/60),58.3%(35/60),3.3%(2/60),respectively;the differences between two groups was statistically significant(χ2=6.97,P0.05).The carriers of A/A homozygous genotypes had significantly higher plasma LDL-C((3.94±0.96) mmol/L)level than thosewith G/A wild genotype((3.94±0.96) mmol/L vs.(3.29±0.55) mmol/L,t=2.476,P0.05) and HDL-C((1.23±0.34) mmol/L vs.(1.21±0.26) mmol/L;P>0.05) level had not difference.Conclusion The FABP2 gene G54A polymorphism is related to obesity and lipid metabolism abnormality.The allele encoding in FABP2 gene may be a potential factor contributing to promoting lipid metabolism abnormality.
RESUMO
Objective To investigate the expression of SOX4 and C/EBPα mRNA in chronic myeloid leukemia (CML) and their clinical significances. Methods Bone marrow samples from 68 cases of CML including 57 newly diagnosed patients and 11 patients treated with imatinib were collected, and peripheral blood mononuclear cells from 30 healthy people were collected as healthy control. The expression of SOX4 and C/EBPαmRNA and protein levels were detected by RT-PCR and Western blot, respectively. The relations between the expression of SOX4 and C/EBPα and the influences of imatinib on SOX4 and C/EBPα were analyzed. Results The expression level of SOX4 mRNA was increased in newly diagnosed CML patients compared with that of normal control group (6.545 5±1.495 2 vs. 0.059 6±0.018 8, t=3.139, P=0.002 3), but the expression level of C/EBPαmRNA was significantly decreased (0.238 8±0.033 8 vs. 0.810 5±0.056 2, t=9.240, P0.05). The expression level of SOX4 mRNA in 5 patients treated with imatinib was decreased (0.120 6 ±0.044 9 vs. 0.557 9±0.144 8, t=2.885, P=0.020 4), and the expression level of C/EBPαmRNA was increased (0.330 3±0.042 4 vs. 0.150 5±0.046 5, t=2.855, P=0.021 3). The expression level of SOX4 mRNA in 6 patients who developed blast phase during the treatment of imatinib was increased (0.469 9±0.123 0 vs. 0.050 2±0.036 6, t=2.370, P=0.039 3), and the expression level of C/EBPα mRNA was decreased (0.197 9 ±0.064 7 vs. 0.378 7±0.042 9, t=2.327, P=0.042 3). The expression of SOX4 mRNA was negatively correlated with C/EBPα mRNA (t=-0.554 6, P=0.002 8). Conclusions In newly diagnosed CML, the expression level of SOX4 is increased, C/EBPα is decreased compared with that of healthy control, and both have negative correlation. In the patients in blast phase after imatinib treatment, SOX4 gene is up-regulated, and C/EBPα is down-regulated. C/EBPα-SOX4 axis may play a role in the occurrence and development of CML. SOX4 may be a new molecular target for the treatment of CML.
RESUMO
<p><b>OBJECTIVE</b>To investigate the expression and the possible mechanism of the transcription factor C/EBPα in chronic myeloid leukemia（CML).</p><p><b>METHODS</b>Bone marrow samples from 50 CML patients（including 33 patients in chronic phase, 7 in accelerated phase and 10 in blast crisis）and peripheral blood specimens of 20 healthy donors were collected. The expression of C/EBPα gene and the effect of Imatinib on its expression was detected by RT- PCR. C/EBPα gene was inserted into lentivirus expression vector pLVX- EGFP- 3FLAG- Puro by recombinant DNA technology to construct C/EBPα stable expression in K562 cells. Cell proliferation was assayed by CCK-8. The expressions of Foxo3a and Bim genes were detected by RT-PCR.</p><p><b>RESULTS</b>The level of C/EBPα expression was significantly declined in CML patients compared with that of normal control group（P<0.01）and had negative correlation with bcr- abl expression（Spearman r=－ 0.505, P<0.01). The stable K562- C/EBPα cell line was successfully established and confirmed by RT-PCR and Western blot. Cell proliferation ability was lower in the K562- C/EBPα group than that in the non- transfection and mock-vehicle groups. The expressions of Foxo3a and Bim genes were 1.06 ± 0.06 and 0.53 ± 0.07, respectively, which was higher than that of nontransfection and mock-vehicle groups（P<0.01, P<0.05).</p><p><b>CONCLUSION</b>C/EBPα expression was decreased in CML patients, overexpression of C/EBPα could inhibit K562 cell growth.</p>